3M sees scope for earnings growth as productivity gains and innovation gather pace, says UBS
3M (MMM) Looks Fairly Valued After Its PFAS Settlement Put A Key Risk In View
Wolfe Research Downgrades 3M to Peer Perform
Can 3M Sustain Operating Margin Momentum Amid Sales Growth?
MMM Stock Climbed to an 8.5-Year High on a $7.35 Billion Forever Chemicals Settlement. The Overhang Could Finally Be Lifting.
As Organic Sales Growth Accelerates, 3M Seems Attractive
Is Wall Street Bullish or Bearish on 3M Company Stock?
3M Rises 13.9% in the Past Year: Should You Buy, Sell or Hold the Stock?
3M: Strong Order Momentum And Improving Execution Point To More Upside
3M's Safety & Industrial Growth Picks Up: Can the Momentum Sustain?
Goldman Sachs Maintains Buy on 3M, Raises Price Target to $225
A $7.4 Billion Legal Bill Sounds Bad. For 3M Stock, It’s Pure Relief.
3M settlement removes major PFAS overhang, UBS says
3M (MMM) Expands AI Data Center Optics Push With 500 Job Investment
3M’s “Forever Chemicals” Bill Just Grew by Billions
JP Morgan Maintains Overweight on 3M, Raises Price Target to $210
3M Reaches $7.35B PFAS Personal Injury Settlement, Maintains 2026 Outlook
Is 3M (MMM) Stock Still Cheap After Its $5.8B Settlement?
3M Company Enters $7.35 billion Settlement to Resolve PFAS Personal Injury Claims
3M Company (MMM) Discusses Resolution of AFFF Personal Injury Litigation Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.